NSABP C-06 demonstrated the non-inferiority of oral adjuvant uracil and tegafur plus leucovorin ( UFT/LV ) to weekly fluorouracil and folinate ( 5-FU/LV ) with respect to disease-free survival ( DFS ) for stage II/III colon cancer .